Endoscopic Endonasal Resection of a Pure Optic Canal Cavernous Malformation Presenting as Progressive Optic Neuropathy.

J Neurol Surg A Cent Eur NeurosurgSep 3, 2026 (epub)
Case ReportNeurosurgeryOphthalmology

Daisuke Tanioka, Jyunichiro Kizaki, Ikuya Natori et al.

✦ AI-curated · Sources linked

Case in brief

A 48-year-old woman presented with a 3-month history of progressive right visual decline, characterized by decreased visual acuity and visual field narrowing. MRI revealed a well-defined mass in the right optic canal. After transient improvement with corticosteroids, she underwent endoscopic endonasal surgery, which successfully removed the cavernous malformation. Postoperatively, her vision fully recovered, and imaging confirmed complete resection.

Diagnostic / clinical pearl

Clinicians should consider cavernous malformations as a potential cause of progressive optic neuropathy, especially when imaging reveals a well-circumscribed mass in the optic canal.

Why it matters

This case underscores the effectiveness of the endoscopic endonasal approach for resecting optic canal lesions, contributing to improved visual outcomes.

Source

PubMed · PMID 42692082

Published in J Neurol Surg A Cent Eur Neurosurg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.